Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD).
The active ingredient in proprietary CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcohol while producing a euphoric alcohol-like experience.